Assess whether the primary endpoint will survive FDA scrutiny (fa6017)

SITUATION The working file is CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module. Pediatric-plan strategist in a biologics company planning a biosimilar pathway has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Pharmacovigilance file.

DECISION Pediatric-plan strategist in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. CMC comparability package for a site change reads as Proceed under protocol once a CMO 483 that maps to the NDA CMC module is lined up to the same Pharma & Life Sciences population. 2. CMC comparability package for a site change is closer to Pause the pathway after a CMO 483 that maps to the NDA CMC module; Proceed under protocol would over-claim this Pharmacovigilance extract. 3. Escalate safety review is still live in CMC comparability package for a site change for pediatric-plan strategist in a biologics company planning a biosimilar pathway. 4. CMC comparability package for a site change is missing the fact pediatric-plan strategist needs after a CMO 483 that maps to the NDA CMC module; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on the primary endpoint will. 3. Check whether CMC comparability package for a site change supports the labeled claim pediatric-plan strategist would keep. 4. For this Pharma & Life Sciences Pharmacovigilance file, read CMC comparability package for a site change against a CMO 483 that maps to the NDA CMC module and write the one fact that would move the primary endpoint will for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (CMC comparability package for a site change after a CMO 483 that maps to the NDA CMC module). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a CMO 483 that maps to the NDA CMC module, then the two facts that force it, then the Monday action for pediatric-plan strategist in a biologics company planning a biosimilar pathway.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the primary endpoint will, then the evidence in CMC comparability package for a site change, then the action for pediatric-plan strategist - Hypothesis scorecard against CMC comparability package for a site change: supported / rejected / untestable - Regulatory or exam hook Pharmacovigilance would cite - Pharmacovigilance finding in CMC comparability package for a site change that a second reviewer can re-perform